lti-03
Peptideexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2020 (NCT04233814)
Timeline
Indications
Studied for
Mechanism of action
- Caveolin-1INHIBITOR
CAV1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068584 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06968845 | Phase 2 | May 2, 2025 | Rein Therapeutics |
| NCT05954988 | Phase 1 | Jul 6, 2023 | Lung Therapeutics, Inc, Rein Therapeutics |
| NCT04233814 | Phase 1 | Jan 6, 2020 | Celerion, Lung Therapeutics, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lung Therapeutics, Inc | For profit | 2 | 2 | 1 | 2020 |
| Rein Therapeutics | For profit | 2 | 2 | 2 | 2023 |
| Celerion | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1